Published online September 1, 2006
PEDIATRICS Vol. 118 No. 3 September 2006, pp. 1287-1292 (doi:10.1542/peds.2006-1722)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Therapeutics & Toxicology

POLICY STATEMENT

The Use of Systemic Fluoroquinolones

Committee on Infectious Diseases

The only indications for which a fluoroquinolone (ie, ciprofloxacin) is licensed by the US Food and Drug Administration for use in patients younger than 18 years are complicated urinary tract infections, pyelonephritis, and postexposure treatment for inhalation anthrax. Nonetheless, approximately 520 000 prescriptions for fluoroquinolones were written in the United States for patients younger than 18 years in 2002; 13 800 were written for infants and children 2 to 6 years of age, and 2750 were written for infants younger than 2 years. Clinical trials of fluoroquinolones in pediatric patients with various diagnoses have been published and are reviewed. Fluoroquinolones cause arthrotoxicity in juvenile animals and have been associated with reversible musculoskeletal events in both children and adults. Other adverse events associated with fluoroquinolones include central nervous system disorders, photosensitivity, disorders of glucose homeostasis, prolongation of QT interval with rare cases of torsade de pointes (often lethal ventricular arrhythmia in patients with long QT syndrome), hepatic dysfunction, and rashes. The increased use of fluoroquinolones in adults has resulted in increased bacterial resistance to this class of antibacterial agents. This report provides specific guidelines for the systemic use of fluoroquinolones in children. Fluoroquinolone use should be restricted to situations in which there is no safe and effective alternative to treat an infection caused by multidrug-resistant bacteria or to provide oral therapy when parenteral therapy is not feasible and no other effective oral agent is available.

Key Words: fluoroquinolones • ciprofloxacin • antibacterial agents • antimicrobial agents • antibiotics

Abbreviations: FDA—Food and Drug Administration • CF—cystic fibrosis • MIC—minimum inhibitory concentration




This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. Cui, J. Li, Z. Sun, C. Hu, S. Jin, F. Li, Y. Guo, L. Ran, and Y. Ma
Characterization of Salmonella enterica isolates from infants and toddlers in Wuhan, China
J. Antimicrob. Chemother., January 1, 2009; 63(1): 87 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
K. A. Pesaturo, E. Z. Ramsey, P. N. Johnson, and L. M. Taylor
Introduction to pediatric pharmacy practice: Reflections of pediatrics practitioners
Am. J. Health Syst. Pharm., July 15, 2008; 65(14): 1314 - 1319.
[Full Text] [PDF]

Home page
 JAMAHome page
M. E. Pichichero and J. R. Casey
Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7-Valent Conjugate Vaccine as an Otopathogen in Children
JAMA, October 17, 2007; 298(15): 1772 - 1778.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Protzko, L. Bowman, M. Abelson, A. Shapiro, and for the AzaSite Clinical Study Group
Phase 3 Safety Comparisons for 1.0% Azithromycin in Polymeric Mucoadhesive Eye Drops versus 0.3% Tobramycin Eye Drops for Bacterial Conjunctivitis
Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3425 - 3429.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Pfister, D. Mazur, J. Vormann, and R. Stahlmann
Diminished Ciprofloxacin-Induced Chondrotoxicity by Supplementation with Magnesium and Vitamin E in Immature Rats
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1022 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 AAP NewsHome page
J. Bradley
Fluoroquinolones in children addressed in AAP policy
AAP News, September 1, 2006; 27(9): 1 - 5.
[Full Text]

eLetters:

Read all eLetters

Prophylaxis for foot wounds against Pseudomonas
Hitesh Z Shah
Pediatrics Online, 4 Sep 2006 [Full text]